Aditxt 2025 Q3 Earnings Net Loss Widens by 246.8% Despite EPS Improvement

Aditxt (ADTX) reported its fiscal 2025 Q3 earnings on Nov 18, 2025, revealing a sharp revenue decline and a significant widening of its net loss. The company’s financial performance underscored persistent operational challenges, with a 4.9% drop in stock price during the latest trading day.

Revenue

The company generated $748 in sales revenue during the quarter, with total revenue remaining unchanged at the same level. This represents an 89.1% year-over-year decline from $6,854 in Q3 2024, reflecting substantial headwinds in its core business.

Earnings/Net Income

Aditxt narrowed per-share losses to $548.78 from $3,137,695.20 in 2024 Q3, a 99.9% improvement. However, the net loss expanded to $24.21 million in Q3 2025, a 246.8% increase from $6.98 million in the prior-year period. The company has now posted losses for four consecutive years in the same quarter, highlighting ongoing financial instability. While per-share losses improved, the net loss expansion underscores systemic operational challenges.

Price Action

Following the earnings release, Aditxt’s stock experienced mixed short-term performance, with a 4.9% decline on the latest trading day and a 30.96% drop over the past week. However, the stock surged 1,151.15% month-to-date, indicating strong investor interest despite the company’s financial struggles.

CEO Commentary

CEO Commentary

Amro Albanna, Co-founder and CEO of Aditxt, emphasized the company’s strategic pivot to bitXbio, a blockchain-driven platform aimed at integrating public markets and health innovations. He noted, “The bitXbio strategy is a structural evolution and we believe it will be the blueprint for transforming how health innovations are discovered, built, and commercialized on a global scale.” Albanna acknowledged the Q3 financial results but stressed that the transition aligns with long-term growth objectives, including the planned IPO of Pearsanta and Evofem’s efforts to regain a national listing.

Guidance

Guidance

The company did not provide specific quantitative guidance for future periods in the Q3 earnings report. However, it reiterated its focus on the bitXbio strategy, including the proposed Employee Stock Purchase Plan, digital asset treasury, and the commercialization of Pearsanta’s Mitomic® and Adductomics testing platforms. Forward-looking statements included Pearsanta’s anticipated 2026 IPO and Evofem’s pursuit of a national exchange listing, though these remain subject to market conditions and regulatory approvals.

Additional News

Aditxt announced a strategic rebranding to bitXbio, Inc., seeking shareholder approval for a name change and an employee stock purchase plan to align stakeholders. The bitXbio strategy aims to leverage blockchain and digital assets to advance health innovations, with a planned digital asset treasury as a key component. Additionally, Pearsanta, Aditxt’s precision diagnostics subsidiary, disclosed plans for a 2026 IPO to commercialize its cancer detection technologies, while Evofem, a portfolio company, outlined efforts to regain a national listing and secure growth capital. These initiatives underscore Aditxt’s broader 2026 monetization and growth strategy.